It is being tested to combine ganitumab with Src inhibitor dasatinib in patients with embryonal and alveolar rhabdomyosarcoma, and with chemotherapy, radiotherapy or CDK4/6 inhibitor in Ewing sarcoma (Table 1). This evidence concerns the gene SRC and rhabdomyosarcoma.